Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs IQIYI Inc - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while IQIYI Inc - ADR trades at $1.15 (market cap $1.09B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 36.6× IQIYI Inc - ADR's market cap. Which is the better fit depends on your goals.
| ALNY | IQ | |
|---|---|---|
Market Cap | $39.89B | $1.09B |
Sector | Health | Media |
52-Week High | $491.22 | $2.79 |
52-Week Low | $278.09 | $0.96 |
Enterprise Value | $38.15B | $2.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IQ trades at $1.13, down 0.88% on the day, with technical indicators neutral and mixed earnings history. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, though valuation ratios like P/S of 0.28 and P/B of 0.57 suggest potential undervaluation. Recent news highlights AI initiatives and leadership changes, while cash flow trends show volatility with a net inflow of $787.41M in 2025.
The outlook is cautious; analyst consensus is split with 50% buy ratings but profitability concerns persist. Risks include revenue declines, competitive pressures in streaming, and debt levels. Upside potential exists if AI-driven content strategies revive growth, but near-term volatility is likely amid earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
